range of pharmaceutical compounds
Magnetic Control of Polymorphism
high magnetic fields
direct polymorphism
desired polymorph
effects of magnetic fields
application of magnetic fields
desired properties
desired crystal
largest pharmaceutical companies
new pharmaceuticals
new discovery
development
aim
major international effort
lowest-energy polymorph
processable form
high-worth generic drugs
properties of carbamazepine
synthetic effort
solid form issues
international multidisciplinary approach
organic crystal growth
representative generic drug molecules
initial stages of MagnaPharm responsible
crystallizing
results
profound theoretical understanding
production
edge spectroscopic
coronene
proposal
indomethacin
H2020-FETOPEN
transformative effect
crystallographic characterisations
project partner AstraZeneca
sales
goal
world
paradigm
innovation
method
year
society
prospect
ability